| Literature DB >> 32569585 |
Anna Coppo1, Giacomo Bellani2, Dario Winterton3, Michela Di Pierro3, Alessandro Soria4, Paola Faverio5, Matteo Cairo1, Silvia Mori6, Grazia Messinesi7, Ernesto Contro1, Paolo Bonfanti8, Annalisa Benini1, Maria Grazia Valsecchi6, Laura Antolini6, Giuseppe Foti3.
Abstract
BACKGROUND: The COVID-19 pandemic is challenging advanced health systems, which are dealing with an overwhelming number of patients in need of intensive care for respiratory failure, often requiring intubation. Prone positioning in intubated patients is known to reduce mortality in moderate-to-severe acute respiratory distress syndrome. We aimed to investigate feasibility and effect on gas exchange of prone positioning in awake, non-intubated patients with COVID-19-related pneumonia.Entities:
Mesh:
Year: 2020 PMID: 32569585 PMCID: PMC7304954 DOI: 10.1016/S2213-2600(20)30268-X
Source DB: PubMed Journal: Lancet Respir Med ISSN: 2213-2600 Impact factor: 30.700
Figure 1Prone positioning with a helmet interface to enable continuous positive airway pressure
Example demonstrated by volunteer.
Figure 2Study profile
Responders were defined as patients with an increased ratio of partial pressure of oxygen to fractional concentration of oxygen in inspired air between SP1 to SP2 for the main analysis. All other patients who were successfully put in the prone position were non-responders. SP1=baseline supine position. SP2=1 h after resuming supine position.
Baseline demographic and clinical characteristics of analysable population
| Age, years | 57·4 (7·4) | |
| Sex | ||
| Female | 12 (21%) | |
| Male | 44 (79%) | |
| BMI, kg/m2 | 27·5 (3·7) | |
| Time between symptom onset and admission to hospital, days | 7·8 (4·2) | |
| Time between admission to hospital and prone positioning, days | 3·5 (3·1) | |
| Comorbidities | ||
| Previous myocardial infarction | 4 (7%) | |
| Congestive heart failure | 0 | |
| Hypertension | 23 (41%) | |
| Vascular disease | 3 (5%) | |
| Chronic bronchopulmonary disease | 2 (4%) | |
| Gastric or liver disease | 3 (5%) | |
| Diabetes | 8 (14%) | |
| Moderate-to-severe chronic kidney disease (eGFR <59 mL/min) | 0 | |
| Solid malignancy | 3 (5%) | |
| Smoking history | ||
| Active smoker | 1 (2%) | |
| Former smoker (<1 year) | 1 (2%) | |
| Former smoker (≥1 year) | 20 (36%) | |
| Never smoked | 29 (52%) | |
| Not declared | 5 (9%) | |
| Oxygen delivery interface | ||
| Helmet CPAP | 44 (79%) | |
| Reservoir mask | 9 (16%) | |
| Venturi mask | 3 (5%) | |
Data are n (%) or mean (SD). BMI=body-mass index. CPAP=continuous positive airway pressure. eGFR=estimated glomerular filtration rate.
Study timepoint analysis among patients who tolerated prone positioning and had available data across the three study timepoints (n=46)
| Difference (95% CI) | p value | Difference (95% CI) | p value | |||||
|---|---|---|---|---|---|---|---|---|
| FiO2, % | 68·9 (19·8) | 68·9 (19·8) | 65·9 (20·2) | 0·0 (0·0 to 0·0) | 1·0 | 3·0 (−0·7 to 6·8) | 0·11 | |
| PEEP, cm H2O | 8·3 (2·3) | 8·3 (2·3) | 8·3 (2·3) | 0·1 (−0·1 to 0·2) | 1·0 | 0·2 (−0·1 to 0·2) | 0·32 | |
| Arterial blood gas | ||||||||
| pH | 7·46 (0·03) | 7·46 (0·04) | 7·46 (0·03) | 0·0 (0·0 to 0·0) | 0·50 | 0·0 (0·0 to 0·0) | 0·08 | |
| PaO2, mm Hg | 117·1 (47·4) | 200·4 (110·9) | 121·4 (69·6) | 83·3 (56·1 to 110·4) | <0·0001 | 4·3 (−13·2 to 21·6) | 0·60 | |
| PaO2/FiO2 ratio, mm Hg | 180·5 (76·6) | 285·5 (112·9) | 192·9 (100·9) | 104·9 (70·9 to 134·0) | <0·0001 | 12·3 (−10·9 to 35·5) | 0·29 | |
| PaCO2, mm Hg | 35·3 (4·9) | 35·6 (4·5) | 35·5 (4·4) | 0·4 (−1·3 to 0·6) | 0·48 | 0·3 (−0·9 to 1·4) | 0·64 | |
| SaO2, % | 97·2 (2·0) | 98·4 (1·3) | 97·1 (2·0) | 1·2 (0·8 to 1·7) | <0·0001 | 0·1 (−1·0 to 0·4) | 0·35 | |
| SpO2, % | 97·2 (2·8) | 98·2 (2·2) | 97·1 (1·9) | 1·0 (0·3 to 2·0) | 0·01 | 0·1 (−0·8 to 1·0) | 0·87 | |
| Respiratory rate, breaths per min | 24·5 (5·5) | 24·5 (6·9) | 23·9 (6·3) | 0·1 (−1·0 to 1·5) | 0·71 | −0·6 (−2·0 to 0·8) | 0·40 | |
| Use of accessory respiratory muscles | 9 (20%) | 7 (15%) | 5 (11%) | −4·4% (−15·0 to 6·2) | 0·32 | −8·7% (− 22·7 to 5·3) | 0·16 | |
| Dyspnoea | 7 (15%) | 4 (9%) | 2 (4%) | −6·5% (− 19·8 to 6·8) | 0·26 | −10·9% (− 23·8 to 2·1) | 0·06 | |
| Comfort | .. | .. | .. | .. | 0·23 | .. | 0·06 | |
| Unacceptable | 0 | 0 | 0 | .. | .. | .. | .. | |
| Acceptable | 10 (22%) | 15 (33%) | 4 (9%) | .. | .. | .. | .. | |
| Good | 23 (50%) | 19 (41%) | 24 (52%) | .. | .. | .. | .. | |
| Excellent | 13 (28%) | 12 (26%) | 17 (37%) | .. | .. | .. | .. | |
Data are mean (SD) or n (%), unless otherwise indicated. p values were calculated using Student's t test for continuous variables and the χ2 test for categorical variables. FiO2=fractional concentration of oxygen in inspired air. PaCO2=arterial partial pressure of carbon dioxide. PaO2=arterial partial pressure of oxygen. PEEP=positive end-expiratory pressure. SaO2=arterial oxygen saturation of haemoglobin. SP1=baseline supine position. PP1=10 min after prone positioning. SP2=1 h after resuming supine position. SpO2=peripheral oxygen saturation of haemoglobin.
A comparative analysis of comfort was done across all categories.
Figure 3Per-patient trajectory of PaO2/FiO2 at the three study timepoints, SP1, PP1, and SP2, for responders (A) and non-responders (B)
Each line is the trajectory of one patient, with datapoints showing the PaO2/FiO2 ratio at the three timepoints. Responders were defined as patients with an increased PaO2/FiO2 ratio between SP1 to SP2 for the main analysis. All other patients who were successfully put in the prone position were non-responders. PaO2=partial pressure of oxygen. FiO2=fractional concentration of oxygen in inspired air. SP1=baseline supine position. PP1=10 min after prone positioning. SP2=1 h after resuming supine position.
Comparison between responders and non-responders
| Age, years | 58·5 (7·5) | 55·9 (7·0) | 2·7 (−7·0 to 1·7) | 0·22 | |
| Sex | .. | .. | .. | 1·0 | |
| Female | 6 (26%) | 6 (26%) | .. | .. | |
| Male | 17 (74%) | 17 (74%) | .. | .. | |
| BMI, kg/m2 | 27·3 (3·5) | 27·4 (3·7) | −0·12 (−2·3 to 2·1) | 0·92 | |
| Time between symptom onset and admission to hospital, days | 8·1 (4·8) | 7·4 (4·3) | −0·7 (−3·4 to 1·9) | 0·58 | |
| Time between admission to hospital and prone positioning, days | 2·7 (2·1) | 4·6 (3·7) | −1·9 (−3·7 to 0·1) | 0·04 | |
| Time between symptom onset and prone positioning, days | 10·8 (4·9) | 12·0 (4·3) | −1·1 (−3·9 to 1·6) | 0·41 | |
| Comorbidities | |||||
| Previous myocardial infarction | 1 (4%) | 1 (4%) | .. | .. | |
| Congestive heart failure | 0 | 0 | .. | .. | |
| Hypertension | 9 (39%) | 9 (39%) | .. | .. | |
| Vascular disease | 0 | 3 (13%) | .. | .. | |
| Chronic bronchopulmonary disease | 1 (4%) | 0 | .. | .. | |
| Gastric or liver disease | 1 (4%) | 1 (4%) | .. | .. | |
| Diabetes | 4 (17%) | 2 (9%) | .. | .. | |
| Moderate-to-severe chronic kidney disease (eGFR <59 mL/min) | 0 | 0 | .. | .. | |
| Solid malignancy | 1 (4%) | 2 (9%) | .. | .. | |
| Smoking history | |||||
| Active smoker | 0 | 1 (4%) | .. | .. | |
| Former smoker (<1 year) | 0 | 1 (4%) | .. | .. | |
| Former smoker (≥1 year) | 9 (39%) | 7 (30%) | .. | .. | |
| Never smoked | 12 (52%) | 13 (57%) | .. | .. | |
| Not declared | 2 (9%) | 1 (4%) | .. | .. | |
| Baseline blood values | |||||
| Sodium, mmol/L | 137·7 (2·6) | 138·78 (3·9) | −1·1 (− 3·1 to 0·9) | 0·27 | |
| Potassium, mmol/L | 3·9 (0·5) | 4·1 (0·6) | −0·2 (−0·5 to 0·1) | 0·21 | |
| Chlorine, mmol/L | 101·8 (3·3) | 100·2 (3·6) | 1·6 (−3·7 to 0·5) | 0·13 | |
| Creatinine, mg/dL | 0·9 (0·2) | 0·8 (0·2) | 0·0 (0·0 to 0·0) | 0·21 | |
| Urea, mg/dL | 31·0 (8·2) | 30·3 (8·0) | 0·7 (−5·8 to 4·4) | 0·78 | |
| White blood cells, 103/μL | 7·7 (3·6) | 7·3 (3·0) | 0·3 (−2·3 to 1·6) | 0·75 | |
| Platelets, 103/μL | 241·1 (101·9) | 319·8 (120·6) | −78·7 (−145·0 to 12·3) | 0·02 | |
| Haemoglobin, g/dL | 12·8 (2·0) | 12·4 (1·3) | 0·4 (−1·4 to 0·6) | 0·40 | |
| Haematocrit, % | 37·5 (5·5) | 36·5 (4·1) | 1·0 (−3·9 to 1·9) | 0·50 | |
| Bilirubin, mg/dL | 0·6 (0·5) | 0·5 (0·3) | 0·0 (−0·3 to 0·1) | 0·50 | |
| C-reactive protein, mg/L | 12·7 (6·9) | 8·4 (6·2) | 4·3 (8·3 to 0·3) | 0·03 | |
| Procalcitonin, ng/mL | 0·6 (1·1) | 0·4 (0·4) | 0·3 (−0·9 to 0·4) | 0·44 | |
| Lactate dehydrogenase, U/L | 449·7 (199·0) | 337·9 (94·1) | 111·8 (15·0 to 208·5) | 0·02 | |
| Aspartate aminotransferase, U/L | 49·7 (26·5) | 48·0 (24·4) | 1·7 (−18·7 to 15·2) | 0·83 | |
| Alanine aminotransferase, U/L | 49·4 (37·5) | 57·7 (37·0) | −8·2 (−31·2 to 14·7) | 0·47 | |
| International normalised ratio | 1·3 (0·6) | 1·1 (0·1) | 0·2 (−0·4 to 0·1) | 0·24 | |
| Activated partial thromboplastin time ratio | 1·1 (0·1) | 1·0 (0·1) | 0·0 (−0·1 to 0·0) | 0·43 | |
| D-dimer, ng/mL | 576·4 (432·2) | 632·9 (431·8) | −56·5 (−342·4 to 229·3) | 0·69 | |
| Arterial blood gas at SP1 | |||||
| pH | 7·46 (0·0) | 7·5 (0·0) | 0·0 (0·0 to 0·0) | 0·79 | |
| PaO2, mm Hg | 114·5 (49·1) | 119·7 (46·7) | −5·2 (−33·6 to 23·3) | 0·72 | |
| PaCO2, mm Hg | 35·1 (5·2) | 35·4 (4·6) | −0·3 (−3·2 to 2·6) | 0·85 | |
| SaO2, % | 97·1 (2·1) | 97·3 (1·9) | −0·2 (−1·4 to 1·0) | 0·73 | |
| Arterial blood gas at PP1 | |||||
| pH | 7·5 (0·0) | 7·5 (0·0) | 0·0 (0·0 to 0·0) | 0·44 | |
| PaO2, mm Hg | 225·3 (112·6) | 175·5 (105·8) | 49·8 (−15·2 to 114·7) | 0·13 | |
| PaCO2, mm Hg | 35·3 (5·4) | 36·0 (3·6) | −0·7 (−3·4 to 2·0) | 0·61 | |
| SaO2, % | 98·5 (1·4) | 98·4 (1·3) | 0·2 (−1·0 to 0·7) | 0·72 | |
| Arterial blood gas at SP2 | |||||
| pH | 7·5 (0·0) | 7·5 (0·0) | 0·0 (0·0 to 0·0) | 0·84 | |
| PaO2, mm Hg | 154·0 (84·9) | 88·7 (21·8) | 65·3 (28·4 to 102·1) | <0·0001 | |
| PaCO2, mm Hg | 35·1 (4·5) | 36·0 (4·3) | −1·0 (−3·6 to 1·7) | 0·47 | |
| SaO2, % | 97·8 (2·1) | 96·4 (1·8) | 1·4 (0·2 to 2·6) | 0·03 | |
| Secondary outcomes | |||||
| Tracheal intubation | 7 (30·4%) | 6 (26·1%) | 4·3 (−30·7 to 21·6) | 0·74 | |
| Time to intubation | 2 (2 to 4) | 2·5 (1·0 to 5·0) | .. | 0·45 | |
| Duration of prone positioning, h | 3·5 (3·0 to 4·0) | 3·5 (3·0 to 4·0) | .. | 0·99 | |
| Prone positioning for >3 h | 12 (52·2%) | 13 (56·5%) | −4·3% (−33·1 to 24·4) | 0·77 | |
| Number of prone positioning cycles | 2 (1 to 3) | 2 (1 to 3) | .. | 0·94 | |
| More than one prone positioning cycle | 12 (52·1%) | 11 (47·8%) | 4·3% (−34·0 to 24·9) | 0·76 | |
Data are mean (SD) or n (%), unless otherwise indicated. Differences are not calculated for data presented as median (range) or for small proportions. p values were calculated using Student's t test for continuous variables and the χ2 test for categorical variables. BMI=body-mass index. CPAP=continuous positive airway pressure. FiO2=fractional concentration of oxygen in inspired air. eGFR=estimated glomerular filtration rate. PaCO2=arterial partial pressure of carbon dioxide. PaO2=arterial partial pressure of oxygen. PEEP=positive end-expiratory pressure. SaO2=arterial oxygen saturation of haemoglobin. SP1=baseline supine position. PP1=10 min after prone positioning. SP2=1 h after resuming supine position. SpO2=peripheral oxygen saturation of haemoglobin.